Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gene Therapy to Target CD22 for Oncology by Kecellitics Biotech for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Gene Therapy to Target CD22 for Oncology is under clinical development by Kecellitics Biotech and currently in Phase II for...
Gene Therapy to Target CD22 for Oncology by Kecellitics Biotech for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Gene Therapy to Target CD22 for Oncology is under clinical development by Kecellitics Biotech and currently in Phase II for...
Gene Therapy to Target CD22 for Oncology by Kecellitics Biotech for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Gene Therapy to Target CD22 for Oncology is under clinical development by Kecellitics Biotech and currently in Phase II for...
Gene Therapy to Target CD22 for Oncology by Kecellitics Biotech for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Gene Therapy to Target CD22 for Oncology is under clinical development by Kecellitics Biotech and currently in Phase II for...